Background Scarce data are available on what variables affect the risk of transmission of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of …

Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …

The relationship between SARS-CoV-2 viral load and infectiousness is poorly known. Using
data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of …

Background Current strategies for preventing severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

We read with interest the recent article by Collins et al. 1 regarding under-identification of
hospital clusters of Group B Streptococcus (GBS) disease outbreaks. The first step in …

Background Mass testing for early identification and isolation of infectious COVID-19 individuals
is efficacious for reducing disease spread. Antigen-detecting rapid diagnostic tests (Ag-…

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed
to assess whether CP administered during the first week of symptoms reduced the disease …

Background In a longitudinal study assessing the WHO strategy for yaws eradication using
mass azithromycin treatment, we observed resurgence of yaws cases with dominance of a …

The study by Lui et al., indicated that an inflammatory immune response is associated with
severe RSV infections in elderly [1, 2]. In children under the age of 5 years respiratory …